تقرير
Inetetamab combined with pyrotinib and chemotherapy in the treatment of breast cancer brain metastasis: A case report.
| العنوان: | Inetetamab combined with pyrotinib and chemotherapy in the treatment of breast cancer brain metastasis: A case report. |
|---|---|
| المؤلفون: | Dou QQ; Graduate Student Institute, Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China., Sun TT; Graduate Student Institute, Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China., Wang GQ; Graduate Student Institute, Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China., Tong WB; Central Breast Area B, Beijing University Cancer Hospital Inner Mongolia Hospital, Hohhot 010000, Inner Mongolia Autonomous Region, China. tongwei365@qq.com. |
| المصدر: | World journal of clinical cases [World J Clin Cases] 2024 Jan 26; Vol. 12 (3), pp. 575-581. |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101618806 Publication Model: Print Cited Medium: Print ISSN: 2307-8960 (Print) Linking ISSN: 23078960 NLM ISO Abbreviation: World J Clin Cases Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014-: Pleasanton, CA : Baishideng Publishing Group Original Publication: Hong Kong, China : Baishideng Publishing Group Co., Limited, [2013]- |
| مستخلص: | Background: Breast cancer brain metastasis (BCBM) is an advanced breast disease that is difficult to treat and is associated with a high risk of death. Patient prognosis is usually poor, with reduced quality of life. In this context, we report the case of a patient with HER-2-positive BCBM treated with a macromolecular mAb (inetetamab) combined with a small molecule tyrosine kinase inhibitor (TKI). Case Summary: The patient was a 58-year-old woman with a 12-year history of type 2 diabetes. She was compliant with regular insulin treatment and had good blood glucose control. The patient was diagnosed with invasive carcinoma of the right breast (T3N1M0 stage IIIa, HER2-positive type) through aspiration biopsy of the ipsilateral breast due to the discovery of a breast tumor in February 2019. Immunohistochemistry showed ER (-), PR (-), HER-2 (3+), and Ki-67 (55-60%+). Preoperative neoadjuvant chemotherapy, i.e. , the AC-TH regimen (epirubicin, cyclophosphamide, docetaxel-paclitaxel, and trastuzumab), was administered for 8 cycles. She underwent modified radical mastectomy of the right breast in November 2019 and received tocilizumab targeted therapy for 1 year. Brain metastasis was found 9 mo after surgery. She underwent brain metastasectomy in August 2020. Immunohistochemistry showed ER (-) and PR. (-), HER-2 (3+), and Ki-67 (10-20%+). In November 2020, the patient experienced headache symptoms. After an examination, tumor recurrence in the original surgical region of the brain was observed, and the patient was treated with inetetamab, pyrotinib, and capecitabine. Whole-brain radiotherapy was recommended. The patient and her family refused radiotherapy for personal reasons. In September 2021, a routine examination revealed that the brain tumor was considerably larger. The original systemic treatment was continued and combined with intensity-modulated radiation therapy for brain metastases, followed by regular hospitalization and routine examinations. The patient's condition is generally stable, and she has a relatively high quality of life. This case report demonstrates that in patients with BCBM and resistance to trastuzumab, inetetamab combined with pyrotinib and chemotherapy can prolong survival. Conclusion: Inetetamab combined with small molecule TKI drugs, chemotherapy and radiation may be an effective regimen for maintaining stable disease in patients with BCBM. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | J Clin Oncol. 2018 Sep 20;36(27):2804-2807. (PMID: 29939840) Clin Cancer Res. 2019 Nov 15;25(22):6570-6580. (PMID: 31213459) J Transl Int Med. 2022 Mar 5;11(3):226-233. (PMID: 37662890) Ann Oncol. 2022 Mar;33(3):321-329. (PMID: 34954044) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Lancet Oncol. 2021 Mar;22(3):351-360. (PMID: 33581774) Int J Cancer. 2014 Sep 15;135(6):1390-8. (PMID: 24615495) Lancet Oncol. 2015 Dec;16(16):1583-4. (PMID: 26596673) Cancer. 2017 Jun 15;123(12):2283-2293. (PMID: 28192598) MAbs. 2010 Mar-Apr;2(2):181-9. (PMID: 20150767) J Clin Neurosci. 2018 Mar;49:48-55. (PMID: 29248376) Breast Cancer Res. 2011;13(6):R123. (PMID: 22129105) JAMA Oncol. 2021 Apr 01;7(4):573-584. (PMID: 33480963) Cancer Commun (Lond). 2021 Aug;41(8):747-795. (PMID: 34197702) Cancer Immunol Res. 2016 Nov;4(11):895-902. (PMID: 27803050) |
| فهرسة مساهمة: | Keywords: Breast cancer brain metastasis; Case report; HER2-positive; Macromolecule inetetamab; Radiation therapy; Resistance to trastuzumab; Small molecule tyrosine kinase inhibitor |
| تواريخ الأحداث: | Date Created: 20240207 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10841958 |
| DOI: | 10.12998/wjcc.v12.i3.575 |
| PMID: | 38322469 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2307-8960 |
|---|---|
| DOI: | 10.12998/wjcc.v12.i3.575 |